Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Harry Ehrlich who wrote (1078)	2/1/1998 3:29:00 PM
From: D.Right	Respond to of 2173

Dear Harry: Amylin is a peptide hormone, it can not be taken orally because it will be digested in the stomach just like other peptides such as insulin. This is one of the big reasons the street thinks pramlintide will not be widely used. They are wrong. It is true that to inject youself everyday is a huge unconvenience for patients. However, pramlintide is only intended for people using injected insulin already (company says about seven million patients out there, I don't know how accurate the number is). For them, no addition injections at all, just pull insulin and pramlintide into the same syringe. It is like adding cream to your cup of coffee, cream gets taken in from the same cup, the same sip. If you are not a coffee drinker, it would be an additional work, which is not the case here. Even so, for the 75% trial patients I mentioned here earlier, they won't add cream if they don't like the taste. That is why I consider the 75% is huge. Black coffee? D.Right